New regulations threaten heavy costs for Canada's industry
This article was originally published in Clinica
Canada's new device regulations and the associated cost recovery scheme will create substantial increases in costs for medical device manufacturers, say two new independent reports prepared for the Therapeutic Products Programme. Both the regulations and cost recovery are due to come into force on July 1 (see Clinica No 788/89, p 5).
You may also be interested in...
CEO breaks down to Scrip how the Hong Kong-based company managed its way through the coronavirus outbreak in China, saying improvisation was critical.
GNC announces "significant" store and management staff furloughs and other cost-cutting moves "to protect the long-term prospects for the business." Vitamin Shoppe told customers that its stores remain open though it reduced business hours.
California-based biosensor patch company LifeSignals Group plans to file for an emergency use authorization from the US FDA for a new patch that can monitor vital signs to help individuals decide when to seek the help of a health care provider. See what LifeSignals’ CEO Surendar Magar said about it here.